4DMedical 100% Surge: Beginning of a Breakout or the Peak?

4DMedical Doubles in a Month: Momentum or Peak?

A 100 percent share price surge in just one month will always turn heads, but the real question is whether the story has just begun or is already peaking. That’s the situation facing investors watching 4DMedical, a small-cap respiratory imaging company now riding the momentum of two game-changing developments.

First came a 10 million dollar facility from Pro Medicus, one of the world’s most respected medical imaging software players, to fast-track product rollouts and push a flagship technology toward US regulatory clearance. 

Then came a quarterly report that didn’t just meet expectations, it blew them away, with revenue up 56 percent year on year, SaaS revenue almost doubling, and gross margins north of 90 percent.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

4DMedical Product CT: VQ at a Turning Point

At the heart of the story is CT: VQ, software that transforms a standard chest CT into a high-definition map of how air and blood move through the lungs, helping doctors spot subtle issues in minutes. The opportunity is clear as this product seeks FDA approval and may provide another revenue stream for the company, but so are the questions: 

Can 4DMedical scale fast enough, and will the market be ready to pay for it?

4DMedical, What It Does and Who Buys It

4DMedical is an Australian-based company transforming how doctors see and understand lung health. Its technology takes routine chest imaging and turns it into detailed, quantitative maps that reveal how the lungs actually function, measuring ventilation (how easily and evenly fresh air reaches different parts of the lungs) and perfusion (how well blood flows through the tiny vessels to collect oxygen). These insights go beyond what a regular CT scan can show, helping clinicians detect problems earlier and with greater precision.

The company’s product suite includes CT:VQ, which converts a standard chest CT into colour-coded maps of airflow and blood flow, aiming to replace older nuclear medicine scans and is currently awaiting FDA approval. 

CT LVAS analyses CT scans in the cloud to assess lung function region by region, while XV LVAS uses real-time X-ray video to visualise airflow patterns. 

Its Lung Density AI tool, already deployed in partnership with Olympus in the US, detects early signs of lung damage like emphysema.

4DMedical sells primarily to hospitals and leading academic medical centres, including Stanford Medicine and the University of Michigan. Revenue comes through a SaaS model, with per-scan fees and subscription agreements, supported by US reimbursement pathways that make its solutions commercially viable.

Pro Medicus Partnership Powers 4DMedical’s Next Phase

Pro Medicus is one of the most respected imaging software providers in the world, with a customer base that includes leading hospitals such as Mayo Clinic and Johns Hopkins. Its strong capital position and extensive distribution network put it in a unique position to help 4DMedical expand its footprint, increase scan volumes, and accelerate adoption in the US market.

This aligns closely with the company’s current trajectory, as 4DMedical already has two FDA-cleared products, XV LVAS and CT LVAS, and submitted its CT:VQ product for FDA 510(k) clearance in May 2025. The timing of this 10 million dollar senior secured facility means the funds can directly support commercial rollout alongside regulatory progress.

Upside and Risks for Shareholders

From an investor’s perspective, there are clear advantages to this arrangement. Partnering with a high-quality player like Pro Medicus increases the likelihood of successful market entry and scale, especially since 4DMedical’s existing products are already generating revenue. The loan structure also reduces shareholder dilution, since new shares are only issued if the stock more than doubles during the two-year term.

However, the risks are worth noting. The loan is senior and secured, meaning equity holders rank behind Pro Medicus in the event of financial trouble. The 12.5 percent annual interest is significant, and if FDA approval takes longer than expected, cash burn could rise sharply.

For investors, tracking both commercial momentum and regulatory progress will be critical to assessing whether this funding becomes a catalyst for long-term growth or a strain on resources.